Indolent lymphoma · 13 regimens
Cost vs Efficacy · 5 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Bendamustine and Ofatumumab Variant #01 | — | R 1 183 675 | 28d | — | — | ~6 | ~R 3 259 566 indirect | — |
Lenalidomide and Rituximab (R2) Variant #08 | — | R 106 523 | 28d | ~39.4 mo | — | ~13 | ~R 141 371 PFS proxy · indirect | 1 |
PCR Variant #03 Partial | — | R 103 769 | 28d | — | — | ~6 | ~R 208 140 indirect | — |
Bortezomib and Rituximab (VR) Variant #01 | — | R 58 571 | 60d | ~12.8 mo | — | ~5 | ~R 241 048 PFS proxy · indirect | 1 |
R-CMD Variant #01 Partial | — | R 45 471 | 21d | — | — | ~4 | ~R 181 883 indirect | — |
Fludarabine and Rituximab (FR) Variant #01 | — | R 34 157 | 28d | — | — | ~6 | ~R 204 943 indirect | — |
Bendamustine and Rituximab (BR) Variant #01 | — | R 33 874 | 28d | 69.5 mo | — | 6 | R 203 245 PFS proxy | 2 |
VR-CHOP Variant #01 | — | R 30 327 | 21d | — | — | ~6 | ~R 181 963 indirect | — |
R-CHOP Variant #08 | — | R 26 946 | 21d | 44.4 mo | — | 3 | R 80 838 PFS proxy | 1 |
R-CVP Variant #01 | — | R 26 502 | 21d | — | — | ~8 | ~R 212 013 PFS proxy · indirect | 1 |
Chlorambucil monotherapy Variant #03 | — | R 2 355 | 28d | ~12.6 mo | ~69.7 mo | ~13 | ~R 30 610 PFS proxy · indirect | 6 |
Rituximab monotherapy Variant #09 Partial | — | — | 28d | ~17.7 mo | — | ~1 | — | 4 |
Watchful waiting Partial | — | — | — | ~12.9 mo | — | — | — | — |
13 of 13 regimens shown